Biotech Investors’ Happy New Year Is in Jeopardy

Bookmark
(Bloomberg Opinion) -- January has tended to favor biotechnology stocks, and this one has been no exception. Between Bristol-Myers Squibb Co.’s $74 billion bid for industry powerhouse Celgene Corp....
BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.